| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_773bdc8bea35b7d225a07bd9f473edf1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-03 |
| filingDate |
2007-12-07^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08695b87d45bf08c648fafade714fa4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a233c5a9ae29ee2ae65169029fd72ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd66b7c5145bcc81f39ec5b7ff0a97ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d794d30b3645de8fad78fe6e0c75c548
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68110b3f8ca1c9254cfad4002526560b |
| publicationDate |
2009-08-19^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2089513-A1 |
| titleOfInvention |
Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp |
| abstract |
The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity. |
| priorityDate |
2006-12-07^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |